MX2024015303A - Composicion farmaceutica y uso de la misma - Google Patents
Composicion farmaceutica y uso de la mismaInfo
- Publication number
- MX2024015303A MX2024015303A MX2024015303A MX2024015303A MX2024015303A MX 2024015303 A MX2024015303 A MX 2024015303A MX 2024015303 A MX2024015303 A MX 2024015303A MX 2024015303 A MX2024015303 A MX 2024015303A MX 2024015303 A MX2024015303 A MX 2024015303A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- seq
- nos
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210712836 | 2022-06-22 | ||
| PCT/CN2023/087998 WO2023246247A1 (zh) | 2022-06-22 | 2023-04-13 | 药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024015303A true MX2024015303A (es) | 2025-01-09 |
Family
ID=89218472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015303A MX2024015303A (es) | 2022-06-22 | 2024-12-10 | Composicion farmaceutica y uso de la misma |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250129163A1 (https=) |
| EP (1) | EP4321537A4 (https=) |
| JP (1) | JP2025520232A (https=) |
| KR (1) | KR20250026284A (https=) |
| CN (1) | CN117257934A (https=) |
| AU (1) | AU2023287932A1 (https=) |
| CA (1) | CA3208473A1 (https=) |
| IL (1) | IL317556A (https=) |
| MX (1) | MX2024015303A (https=) |
| WO (1) | WO2023246247A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20252392A1 (es) | 2022-12-12 | 2025-10-10 | Lanova Medicines Ltd | Anticuerpos biespecificos que se dirigen a pd1 y vegf |
| WO2025201450A1 (zh) * | 2024-03-27 | 2025-10-02 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| CA3090878A1 (en) * | 2018-02-11 | 2019-08-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| PH12022551278A1 (en) * | 2019-11-25 | 2023-11-20 | Akeso Biopharma Inc | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| CN110960543A (zh) * | 2019-12-10 | 2020-04-07 | 安徽瀚海博兴生物技术有限公司 | 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物 |
| CN113214400B (zh) * | 2020-01-21 | 2022-11-08 | 甫康（上海）健康科技有限责任公司 | 一种双特异性抗pd-l1/vegf抗体及其用途 |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| US20230159655A1 (en) * | 2020-04-22 | 2023-05-25 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| WO2022083049A1 (zh) * | 2020-10-19 | 2022-04-28 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
-
2023
- 2023-04-13 KR KR1020257001892A patent/KR20250026284A/ko active Pending
- 2023-04-13 US US18/264,242 patent/US20250129163A1/en active Pending
- 2023-04-13 CA CA3208473A patent/CA3208473A1/en active Pending
- 2023-04-13 AU AU2023287932A patent/AU2023287932A1/en active Pending
- 2023-04-13 IL IL317556A patent/IL317556A/en unknown
- 2023-04-13 JP JP2023547426A patent/JP2025520232A/ja active Pending
- 2023-04-13 CN CN202310398592.6A patent/CN117257934A/zh active Pending
- 2023-04-13 WO PCT/CN2023/087998 patent/WO2023246247A1/zh not_active Ceased
- 2023-04-13 EP EP23745372.5A patent/EP4321537A4/en active Pending
-
2024
- 2024-12-10 MX MX2024015303A patent/MX2024015303A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025520232A (ja) | 2025-07-03 |
| CN117257934A (zh) | 2023-12-22 |
| KR20250026284A (ko) | 2025-02-25 |
| AU2023287932A1 (en) | 2024-12-12 |
| WO2023246247A1 (zh) | 2023-12-28 |
| EP4321537A1 (en) | 2024-02-14 |
| EP4321537A4 (en) | 2025-04-23 |
| IL317556A (en) | 2025-02-01 |
| CA3208473A1 (en) | 2023-12-22 |
| US20250129163A1 (en) | 2025-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015303A (es) | Composicion farmaceutica y uso de la misma | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| ZA202400787B (en) | Pharmaceutical composition and use | |
| PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| PE20210119A1 (es) | Anticuerpos anti-apoc3 y metodos de uso de estos |